cabozantinib,nivolumab
exelixis,bms
['nivo', 'nivolumab', 'cabozantinib', 'gucsm', 'rcc,(-irccs),(-srcc),(-urcc)']
nivolumab/cabozantinib associated w/ greater proportion of deep objective responses for advanced #rcc #asco22 #ascodailynews #gucsm 
Account of the American Society of Clinical Oncology & its affiliate the Association for Clinical Oncology. Assoc tweets labeled #ASCOAdvocacy. RTs ? endorse.